OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
IRVINE, Calif., May 25, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP). Investors who purchased or otherwise acquired shares between January 7, 2016 and April 28, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the July 17, 2017 lead plaintiff motion deadline.
If you purchased Neurotrope shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Neurotrope made false and/or misleading statements and/or failed to disclose material adverse information about the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, the Company announced “positive top-line results” of the focal Phase 2b trials of Bryostatin-1, mentioning “improvement in patients with moderate to severe Alzheimer's disease.” The trial data negates these statements, however, as the top-line data relating to the 20-microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40-microgram dose in connection with its primary and secondary endpoints. Upon release of this news, Neurotrope’s stock price dropped materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
